EP Patent

EP2997964A1 — Pharmaceutical formulations comprising salts of (5s,8s)-8-[{(1 r)-1-(3,5-bis-trifluoromethyl)phenyl]- ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one and their medical use

Assigned to Opko Health Inc · Expires 2016-03-23 · 10y expired

What this patent protects

Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.

USPTO Abstract

Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1 R)-1-(3,5-Bis-trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP2997964A1
Jurisdiction
EP
Classification
Expires
2016-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Opko Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.